UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $1.12 Billion Stake in Danaher Corporation $DHR

Key Points

• UBS AM reduced its holdings in Danaher Corporation by 4.0% during the first quarter, now owning approximately 5.4 million shares valued at over $1.1 billion.
• In contrast, several other institutional investors, including Woodline Partners LP and Ascent Group LLC, increased their stakes in Danaher during the same period.
• Danaher received multiple upgrades, with analysts from firms like Barclays and Robert W. Baird raising their price targets and ratings, reflecting a positive outlook with a consensus target price of $246.35.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lessened its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,447,964 shares of the conglomerate's stock after selling 229,068 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.76% of Danaher worth $1,116,833,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Heck Capital Advisors LLC acquired a new position in shares of Danaher during the 4th quarter worth approximately $27,000. GHP Investment Advisors Inc. grew its position in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC grew its position in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in shares of Danaher during the 1st quarter worth approximately $31,000. Finally, Dunhill Financial LLC grew its position in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after purchasing an additional 67 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 11.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Barclays restated an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Robert W. Baird increased their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. UBS Group reduced their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Wells Fargo & Company lowered their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Finally, Evercore ISI lowered their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, Danaher has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Trading Up 1.4%

Shares of DHR stock traded up $2.64 during trading hours on Thursday, hitting $195.23. 3,425,999 shares of the company's stock traded hands, compared to its average volume of 3,039,142. The stock's 50 day simple moving average is $201.47 and its 200 day simple moving average is $199.04. The stock has a market cap of $139.79 billion, a PE ratio of 41.54, a price-to-earnings-growth ratio of 2.69 and a beta of 0.75. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the previous year, the company posted $1.72 EPS. The business's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.